Renal cell carcinoma in tuberous sclerosis complex

American Journal of Surgical Pathology

Volumn 38, Issue 7, 2014, Pages 895-909

  Yang, Ping ^a,d   Cornejo, Kristine M ^a   Sadow, Peter M ^a   Cheng, Liang ^f   Wang, Mingsheng ^f   Xiao, Yu ^e   Jiang, Zhong ^c   Oliva, Esther ^a   Jozwiak, Sergiusz ^h   Nussbaum, Robert L ^g   Feldman, Adam S ^a   Paul, Elahna ^b   Thiele, Elizabeth A ^b   Yu, Jane J ^a   Henske, Elizabeth P ^a   Kwiatkowski, David J ^a   Young, Robert H ^a   Wu, Chin Lee ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Institute for Human Genetics   (United States)

^h CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

hybrid oncocytic chromophobe tumor; immunohistochemistry; molecular genetics; renal cell carcinoma; succinate dehydrogenase; tuberous sclerosis complex

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CHEMISTRY; CHILD; CHINA; CLASSIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NOMENCLATURE; PATHOLOGY; POLAND; PREDICTIVE VALUE; PROGNOSIS; TUBEROUS SCLEROSIS; TUMOR VOLUME; UNITED STATES; YOUNG ADULT;

KIDNEY NEOPLASMS; ADULT; CARCINOMA, RENAL CELL; CHILD; CHINA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; POLAND; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TERMINOLOGY AS TOPIC; TUBEROUS SCLEROSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; YOUNG ADULT;

EID: 84902547944     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000237     Document Type: Article

References (50)

1. Kwiatkowski DJ, Whittemore VH, Thiele EA. Tuberous Sclerosis Complex: Genes, Clinical features, and Therapeutics. Weinheim: WILEY-VCH verlag GmbH & Co. KGaA; 2010.
2. Narayanan V. Tuberous sclerosis complex: genetics to pathogenesis. Pediatr Neurol. 2003;29: 404-409.
3. Shepherd CW, Gomez MR, Lie JT, et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66: 792-796.
4. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60: 615-621.
5. Bjornsson J, Short MP, Kwiatkowski DJ, et al. Tuberous sclerosisassociated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149: 1201-1208.
6. Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. Urology. 1991;37: 340-343.
7. Kang SG, Ko YH, Kang SH, et al. Two different renal cell carcinomas and multiple angiomyolipomas in a patient with tuberous sclerosis. Korean J Urol. 2010;51: 729-732.
8. Jimenez RE, Eble JN, Reuter VE, et al. Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol. 2001;14: 157-163.
9. Paul E, Thiele EA, Shailam R, et al. Case records of the Massachusetts General Hospital. Case 26-2011. A 7-year-old boy with a complex cyst in the kidney. N Engl J Med. 2011;365: 743-751.
10. Kubo M, Iwashita K, Oyachi N, et al. Two different types of infantile renal cell carcinomas associated with tuberous sclerosis. J Pediatr Surg. 2011;46:E37-E41.
11. Al-Saleem T, Wessner LL, Scheithauer BW, et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998;83: 2208-2216.
12. Schreiner A, Daneshmand S, Bayne A, et al. Distinctive morphology of renal cell carcinomas in tuberous sclerosis. Int J Surg Pathol. 2010;18: 409-418.
13. Duffy K, Al-Saleem T, Karbowniczek M, et al. Mutational analysis of the von Hippel-Lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients. Mod Pathol. 2002;15: 205-210.
14. Pea M, Bonetti F, Martignoni G, et al. Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol. 1998;22: 180-187.
15. Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol. 2000;57: 662-665.
16. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13: 624-628.
17. Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37: 1469-1489.
18. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37: 1490-1504.
19. Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol. 2011;35: 1578-1585.
20. Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36: 1327-1338.
21. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001; 159: 179-192.
22. Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37: 804-815.
23. Cheng L, MacLennan GT, Zhang S, et al. Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. Clin Cancer Res. 2008;14: 8087-8093.
24. Gobbo S, Eble JN, Maclennan GT, et al. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol. 2008;32: 1780-1786.
25. Halat S, Eble JN, Grignon DJ, et al. Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol. 2010;23: 931-936.
26. Jones TD, Eble JN, Wang M, et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res. 2005;11: 7226-7233.
27. Cossu-Rocca P, Eble JN, Delahunt B, et al. Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol. 2006;19: 488-493.
28. Brunelli M, Fiorentino M, Gobbo S, et al. Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors. Histol Histopathol. 2011;26: 1207-1213.
29. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol. 2008;32: 1239-1245.
30. Kim SH, Choi Y, Jeong HY, et al. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma. Virchows Arch. 2011;459: 299-306.
31. Verine J, Pluvinage A, Bousquet G, et al. Hereditary renal cancer syndromes: an update of a systematic review. Eur Urol. 2010;58: 701-710.
32. Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37: 1150-1163.
33. Ross H, Martignoni G, Argani P. Renal cell carcinoma with clear cell and papillary features. Arch Pathol Lab Med. 2012;136: 391-399.
34. Rustin P, Munnich A, Rotig A. Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur J Hum Genet. 2002;10: 289-291.
35. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet. 2004;74: 153-159.
36. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292: 943-951.
37. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100: 1260-1262.
38. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31: 41-51.
39. Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf). 2008;69: 587-596.
40. Housley SL, Lindsay RS, Young B, et al. Renal carcinoma with giant mitochondria associated with germ-line mutation and somatic loss of the succinate dehydrogenase B gene. Histopathology. 2010;56: 405-408.
41. Malinoc A, Sullivan M, Wiech T, et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr Relat Cancer. 2012;19: 283-290.
42. Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma- pheochromocytoma syndromes. Hum Pathol. 2010;41: 805-814.
43. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10: 764-771.
44. Henderson A, Douglas F, Perros P, et al. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam Cancer. 2009;8: 257-260.
45. Gill AJ, Pachter NS, Clarkson A, et al. Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl JMed. 2011;364: 885-886.
46. Delongchamps NB, Galmiche L, Eiss D, et al. Hybrid tumour'oncocytoma- chromophobe renal cell carcinoma' of the kidney: a report of seven sporadic cases. BJU Int. 2009;103: 1381-1384.
47. Pote N, Vieillefond A, Couturier J, et al. Hybrid oncocytic/ chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas. Virchows Arch. 2013;462: 633-638.
48. Hes O, Petersson F, Kuroda N, et al. Renal hybrid oncocytic/ chromophobe tumors-a review. Histol Histopathol. 2013;28: 1257-1264.
49. Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch. 2010;456: 355-365.
50. Waldert M, Klatte T, Haitel A, et al. Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol. 2010;57: 661-665.